Toyokuni Shinya
Department of Pathology and Biological Responses, Graduate School of Medicine, Nagoya University, Nagoya 466-8550, Japan.
Cancer Sci. 2009 Jan;100(1):9-16. doi: 10.1111/j.1349-7006.2008.01001.x. Epub 2008 Oct 23.
Iron is abundant universally. During the evolutionary processes, humans have selected iron as a carrier of oxygen inside the body. However, iron works as a double-edged sword, and its excess is a risk for cancer, presumably via generation of reactive oxygen species. Thus far, pathological conditions such as hemochromatosis, chronic viral hepatitis B and C, exposure to asbestos fibers, as well as endometriosis have been recognized as iron overload-associated risks for human cancer. Indeed, iron is carcinogenic in animal experiments. These reports unexpectedly revealed that there are target genes in iron-induced carcinogenesis and that iron-catalyzed oxidative DNA damage is not random in vivo. Several iron transporters and hepcidin, a peptide hormone regulating iron metabolism, were discovered in the past decade. Furthermore, a recent epidemiological study reported that iron reduction by phlebotomy decreased cancer risk in the apparently normal population. These results warrant reconsideration of the role of iron in carcinogenesis and suggest that fine control of body iron stores would be a wise strategy for cancer prevention.
铁在全球范围内都很丰富。在进化过程中,人类选择了铁作为体内氧气的载体。然而,铁就像一把双刃剑,其过量对癌症来说是一种风险,可能是通过产生活性氧来实现的。到目前为止,诸如血色素沉着症、慢性乙型和丙型病毒性肝炎、接触石棉纤维以及子宫内膜异位症等病理状况已被确认为与铁过载相关的人类癌症风险因素。事实上,铁在动物实验中具有致癌性。这些报告意外地揭示,在铁诱导的致癌过程中存在靶基因,并且铁催化的氧化性DNA损伤在体内并非随机发生。在过去十年中发现了几种铁转运蛋白和铁调素(一种调节铁代谢的肽类激素)。此外,最近一项流行病学研究报告称,通过放血减少铁含量可降低明显正常人群的癌症风险。这些结果值得重新审视铁在致癌过程中的作用,并表明精细控制体内铁储备可能是预防癌症的明智策略。